The outdated fears around estrogen and hormones—and the evidence-based truths every woman deserves.

This weekend, most of us will set our clocks forward and welcome the longer, brighter days ahead. It’s a small act of moving forward — and this National Women’s Month, we think there’s a much bigger one long overdue. It’s time to spring forward on women’s hormonal health by finally letting go of the fear-based myths that have kept millions of women undertreated, underserved, and unnecessarily suffering for more than two decades.

The story begins in 2002, when the Women’s Health Initiative study was halted early and the headlines that followed were alarming: hormones cause cancer. Hormones cause heart attacks. Hormones are dangerous. Almost overnight, hormone therapy use plummeted, a generation of physicians was trained to avoid it, and women were left to manage debilitating symptoms on their own — told it was simply “part of aging.”

What those headlines didn’t tell you: the study used synthetic and animal-derived hormones. Subsequent reanalyses and decades of additional research have told a profoundly different story. And in November 2025, the FDA made it official — removing the black box warnings for cardiovascular disease, breast cancer, and probable dementia from all hormone replacement therapy products. Commissioner Dr. Marty Makary called what happened to women “maybe one of the greatest screw-ups of modern medicine.”

Science was always there. Now the institution has caught up. But the myths it created are still circulating in exam rooms, online forums, and women’s minds everywhere. Here are three of the most damaging ones — and the evidence-based truths that should replace them.

Myth #1: Estrogen causes breast cancer.

What the WHI Data Actually Showed

This is the fear that has done the most damage, and it deserves to be laid to rest clearly and completely. The original WHI study did show an increased breast cancer risk — but that risk was tied specifically to the synthetic progestin medroxyprogesterone acetate (MPA), not to estrogen itself. The FDA’s 2025 label update explicitly acknowledged this distinction, noting that the elevated risk has been linked to medroxyprogesterone acetate, which is a formulation of progesterone not in common use today for hormone therapy.

Estrogen-Alone Therapy and Breast Cancer Outcomes

When we look at estrogen-alone therapy, the data tells a strikingly different story. The WHI follow-up study found that estrogen alone was associated with a 23% reduction in breast cancer incidence and a 44% reduction in breast cancer mortality. A large-scale study of over 10 million Medicare women found that estrogen monotherapy beyond age 65 was associated with a 16% reduction in breast cancer risk. A Finnish nationwide study following nearly 500,000 women found that breast cancer mortality risk was reduced in all hormone therapy users — with even greater reductions in women who used therapy for more than five years.

Bioidentical Progesterone vs. Synthetic Progestins

Bioidentical progesterone tells a similarly reassuring story. The landmark E3N cohort study found that women using bioidentical estradiol with natural progesterone did not have an increased risk of breast cancer — a finding that stands in direct contrast to the risks associated with synthetic progestins.

The myth that estrogen causes breast cancer is not just outdated — for many women, the opposite appears to be true.

Myth #2: Hormones are dangerous for your heart.

Estrogen Deficiency and Cardiovascular Risk in Postmenopausal Women

Cardiovascular disease is the number one killer of women — claiming more lives than all cancers combined. And estrogen deficiency after menopause is one of the most significant drivers of that increased risk. Before menopause, women have dramatically lower rates of heart disease than men of the same age. That protection doesn’t disappear by coincidence — it disappears because estrogen does.

The FDA’s comprehensive review, which drove the November 2025 label changes, cited evidence that HRT initiated within 10 years of menopause onset is associated with a 50% reduction in heart attack risk. Research consistently shows that early initiation of hormone therapy helps maintain vascular elasticity, improves cholesterol profiles, reduces arterial inflammation, and supports healthy blood pressure regulation.

Oral vs. Transdermal Estrogen: Why Delivery Method Matters

The nuance that matters most here is delivery method. Oral estrogen passes through the liver and can increase clotting factors — this is where some cardiovascular risk has been observed. Transdermal estrogen bypasses that first-pass liver metabolism entirely, offering the cardiovascular benefits without that risk. The British Menopause Society, the American Association of Clinical Endocrinology, and the FDA’s updated labeling all recognize transdermal delivery as the preferred approach for women with cardiovascular concerns.

Fear of hormones — not hormones themselves — has likely contributed to the rise in cardiovascular disease among postmenopausal women by denying them one of the most powerful protective tools available.

Myth #3: Hormones accelerate cognitive decline.

The Timing Hypothesis and Brain Protection

This myth originated from a narrow subset of the WHI data involving women over 65 who initiated hormone therapy long after menopause — a population and timing that was never the intended target of the therapy. The FDA’s label update removed the probable dementia warning specifically because it did not reflect the evidence for women initiating therapy at the appropriate time.

What the broader body of research actually shows is the opposite. The Cache County Study found a 59% decrease in the risk of Alzheimer’s disease with 10 years of hormone therapy use. The FDA cited a 64% reduction in cognitive decline and a 35% lower risk of Alzheimer’s disease in its review of the evidence. Nearly two-thirds of Americans with Alzheimer’s are women — this is not a small issue, and timing is everything. Initiating hormone therapy during perimenopause or within 10 years of menopause, before significant neurological changes take hold, appears to offer meaningful protection.

Neuroprotective Effects of Estrogen

Estrogen has well-documented neuroprotective effects — it increases blood flow to the brain, supports neurotransmitter production, reduces neuroinflammation, and promotes the growth of new neural connections. The “brain fog” so many women experience during the menopausal transition is not inevitable. It is a signal of estrogen deficiency, and it is addressable.

The Real Risk: Undertrained Prescribing

The evidence has always been there. The question is who’s been trained to use it. The FDA’s 2025 action was a watershed moment — but it also opened a floodgate. Providers who received minimal menopause training are now suddenly “offering HRT.” Prescriptions are being written after brief appointments with no comprehensive labs, no evaluation of formulation, no attention to delivery method, and no follow-up plan.

Women deserve better than fear-based medicine. They also deserve better than rushed, undertrained care that simply replaces one inadequate approach with another.

Raising the Standard of Care in Hormone Therapy

At the BHRT Training Academy, we train providers in the evidence-based protocols that go far beyond writing a prescription — comprehensive hormone assessment, formulation distinctions, optimal delivery methods, monitoring, and the clinical depth that transforms a prescription into a transformation. Because science is only as powerful as the hands applying it.

This Women’s Month, the most powerful thing we can do for women’s health is this: let go of the myths, follow the evidence, and raise the standard of care. The revolution has been validated. Now it’s time to get to work.